New drugs targeting specific enzymes to treat Alzheimer's disease
Official title: Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-10922848 · Data updated 2026-11-12
This study is testing new potential medications that could help improve memory and behavior in people with Alzheimer's by targeting specific proteins linked to the disease, and it's being done using mice to see how well these treatments work before they can be used in humans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 15, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $661,299 |
| NIH project number | 5R01AG084184-02 |
| Project ID | NIH-10922848 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing new small-molecule inhibitors that target lysine methyltransferases G9a and GLP, which have been linked to the progression of Alzheimer's disease. The project aims to test these inhibitors in mouse models of Alzheimer's to assess their effectiveness in reversing cognitive and behavioral deficits. By optimizing these compounds, the researchers hope to create a viable drug candidate that can be further developed for clinical use in humans. Patients may benefit from a novel treatment option that addresses the underlying mechanisms of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that modifies the course of Alzheimer's disease.
How similar studies have gone: While targeting lysine methyltransferases is a relatively novel approach, preliminary studies have shown promise in related areas of Alzheimer's research.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Jin, Jian — Icahn School of Medicine at Mount Sinai
- Study coordinator: Jin, Jian
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.